MGF (Mechano Growth Factor) vs Vesugen
Side-by-side comparison of key properties, dosing, and research.
Anabolic & IGF
MGF (Mechano Growth Factor)Anti-Aging & Longevity
Vesugen- Summary
- MGF (Mechano Growth Factor) is a splice variant of IGF-1 that is locally produced in muscle tissue in response to mechanical damage from exercise. It activates muscle satellite cells (stem cells) to proliferate and repair damaged fibers, making it specifically targeted at exercise-induced hypertrophy.
- Vesugen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for blood vessels and the vascular endothelium. It supports endothelial cell function, promotes vascular wall integrity, and is studied for atherosclerosis prevention, vascular aging, and cardiovascular health maintenance. It is one of the more broadly applicable Khavinson bioregulators given the ubiquity of vascular tissue.
- Half-Life
- Native MGF: minutes. PEG-MGF: ~3 days
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- SubQ, IM
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 200–400 mcg
- 10 mg per day
- Frequency
- 1–2 times per week
- Daily for 10–30 days
- Key Benefits
- Activates muscle satellite cells for repair and growth
- Accelerates recovery from muscle damage
- Synergistic with IGF-1 LR3 (different mechanisms)
- Promotes muscle hypertrophy specifically at exercised muscles
- Faster recovery between training sessions
- Potential for injury repair in connective tissue
- Supports vascular endothelial cell function and integrity
- May reduce endothelial inflammation and dysfunction
- Anti-aging effects on blood vessel walls
- Potential benefits in early atherosclerosis and vascular aging
- Supports nitric oxide-mediated vascular tone
- Reduces endothelial apoptosis from oxidative stress
- Complementary to Cardiogen and Epithalon in cardiovascular longevity protocols
- Side Effects
- Muscle soreness (satellite cell activation)
- Injection site irritation
- Hypoglycemia risk (modest, less than IGF-1 LR3)
- Generally well tolerated
- Mild injection site reactions
- No significant vascular adverse events reported at standard doses
- Stacks With
- —
- —